Comparative Pharmacology
Head-to-head clinical analysis: FORTAMET versus SYNJARDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAMET versus SYNJARDY.
FORTAMET vs SYNJARDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin inhibits DPP-4, increasing incretin hormone levels (GLP-1, GIP), which stimulate insulin release and decrease glucagon secretion.
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
Initial: 5 mg empagliflozin/1000 mg metformin hydrochloride extended-release orally twice daily with meals. Titrate based on glycemic control, up to maximum of 25 mg/2000 mg per day (given as 12.5 mg/1000 mg twice daily).
None Documented
None Documented
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Empagliflozin: terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: terminal half-life ~6.2 hours in plasma, but prolonged to ~17.6 hours in whole blood due to RBC binding; clinical effect duration aligns with daily dosing.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Renal: ~95% of empagliflozin as unchanged drug; ~20% of metformin as unchanged drug via glomerular filtration and tubular secretion. Fecal: <1% for empagliflozin; ~30% of metformin as unchanged drug. Biliary: negligible.
Category C
Category C
Antidiabetic
Antidiabetic